Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
The oral formulation of BPC-157, distinct from the injectable form in its bioavailability profile and primary applications. While injectable BPC-157 is used for systemic and musculoskeletal healing, oral BPC-157 is particularly relevant for gastrointestinal conditions where direct gut exposure may be more important than systemic absorption.
A tripeptide (Lysine-Proline-Valine) derived from the C-terminus of alpha-MSH (melanocyte-stimulating hormone). Has potent anti-inflammatory properties and is being studied for inflammatory bowel conditions and wound healing.
Same mechanism as injectable BPC-157 — promotes angiogenesis, upregulates growth factors, and modulates nitric oxide synthesis. In oral form, the peptide is exposed directly to the GI tract mucosa before any systemic absorption, potentially making it more effective for gut-specific conditions.
Inhibits NF-κB signaling and pro-inflammatory cytokine production. Crosses the intestinal epithelium to directly suppress inflammation locally. Anti-microbial properties have also been demonstrated in vitro.
- Inflammatory bowel disease (IBD)
- Leaky gut and intestinal permeability
- NSAID-induced gastric damage
- Gut healing and GI protection
- Esophageal and stomach ulcers
- Inflammatory bowel disease (IBD) support
- Wound healing and skin conditions
- General anti-inflammatory protocols
- Gut health optimization
- Lower and more variable systemic bioavailability than injectable
- Limited human clinical data for oral form specifically
- Quality of oral preparations varies significantly
- Long-term safety unknown
- Very limited human clinical data
- Optimal delivery method not established
- Injection vs. oral bioavailability differences not fully characterized
- Long-term safety unknown
Shares the same regulatory status as injectable BPC-157 — removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 23, 2026. The oral form is particularly relevant for the FDA's listed indication of ulcerative colitis. Compounding not yet authorized.
PCAC: July 23, 2026
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 for wound healing and inflammatory conditions. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.